Nektar Therapeutics announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy endpoints from the Phase 1b study. Rezpegaldesleukin is Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, which is being developed for the treatment of atopic dermatitis. The company is presenting the new Phase 1b clinical efficacy endpoints for rez pegaldesleukin at its investor and analyst event on September 13, 2023.

The new data highlight rezpegaldesleUKin's important promise to help patients battling atopic dermatitis, a chronic skin condition that afflicts nearly 10% of Americans.1 The company will also present the trial designs for its Phase 2b study starting in October of rezpegaldes leukin in atopic dermatitis and its new planned Phase 2a study starting in early 2024 in alopecia areata. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of control. The actual results may differ materially from those indicated in the forward-looking statements.

Therefore, you should not rely on any of these forward-looking statements include, among others: (i) statements regarding the therapeutic potential of rezpegaldeslekin are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesle UKin is an investigational agent and continued research and development for this drug candidate is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (not Notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldeslukin is in clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to challenges caused by the COVID-19 pandemic, regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (v) may not achieve the expected cost savings we expect from 2022 corporate restructuring and reorganization plan or 2023 cost restructuring plan and may undertake additional restructuring and cost-saving activities in the future, (vi) patents may not issue from patent applications for drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in Annual Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2023.